Drug Profile
Research programme: muscarinic receptor agonists - Mithridion
Alternative Names: CDD-0097; CDD-0098J; CDD-0199J; CDD-0304; CDD-0312; CDD-0313; CDD-0314; CDD-0316; CDD-0317; CDD-0322; MI-10-022Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator University of Toledo
- Developer Mithridion
- Class Piperidines; Small molecules; Thiadiazoles
- Mechanism of Action Muscarinic M1 receptor agonists; Muscarinic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Alzheimer's disease; Schizophrenia
Highest Development Phases
- No development reported Alzheimer's disease; Schizophrenia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Schizophrenia in USA
- 12 Jan 2011 Research programme: muscarinic receptor agonists - Mithridion is available for licensing as of 12 Jan 2011. http://www.mithridion.com